# EDGAR Filing Document

**Accession Number:** 0001287098
**File Stem:** 0001104659-25-092162
**Filing Date:** 2025-9
**Character Count:** 13967
**Document Hash:** 9e7c53c8d8189150ff9ab374a4e5a564
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-092162.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001104659-25-092162

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250922

**ITEM INFORMATION**: Cost Associated with Exit or Disposal Activities

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250922

**DATE AS OF CHANGE**: 20250922

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAXCYTE, INC.
- **CENTRAL INDEX KEY:** 0001287098
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 522210438
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40674
- **FILM NUMBER:** 251330552

**BUSINESS ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 301-517-5556

**MAIL ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAXCYTE INC
- **DATE OF NAME CHANGE:** 20040415

?xml version='1.0' encoding='ASCII'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 22, 2025**

**MaxCyte, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** |  | **001-40674** |  | **52-2210438** |
| (State or other jurisdiction of <br>incorporation) |  | (Commission File Number) |  | (IRS Employer<br>Identification No.) |

---

**9713 Key West Avenue, Suite 400** 

**Rockville, Maryland 20850**

(Address of principal executive offices, including zip code)

**(301) 944-1700**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **TradingSymbol(s)** | **Name of each exchange** <br>**on which registered** |
| **Common Stock, $0.01 par value** | **MXCT** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.05. Costs Associated with Exit or Disposal Activities.**

On September 22, 2025, the Board of Directors of MaxCyte, Inc. approved a workforce reduction plan (the "Plan") as part of the Company's ongoing efforts to streamline operations, improve its cost structure, and align resources with strategic priorities. The Plan is expected to result in a reduction of approximately 34% of the Company's workforce globally, which includes both directly employed personnel and individuals engaged through third-party employer-of-record ("EOR") arrangements.

In connection with the implementation of the Plan, the Company currently estimates that it will incur an aggregate of approximately $2.9 million of pre-tax, cash charges. The Company expects to incur these charges primarily during the third quarter of 2025 and payment of these charges are expected to occur through Q2 2026. These charges are expected to consist of the following:

● $1.8 million in severance and termination-related benefits for directly employed personnel, including cash severance and healthcare continuation;

● $0.6 million in costs associated with employees engaged through EOR arrangements, including severance, benefits, and statutory notice-period wages administered in accordance with applicable labor laws in jurisdictions such as Germany, France, and the United Kingdom;

● $0.4 million in wages and benefits required under the Maryland Economic Stabilization Act (commonly referred to as the "Mini-WARN Act"), which mandates 60 days' advance notice or pay in lieu thereof for affected employees in Maryland; and

● $0.1 million in other associated costs, including legal fees, consulting services, and administrative expenses related to implementing the Plan.

The actual timing and amount of these charges may differ from the Company's current estimates due to a variety of factors, including the finalization of severance terms, jurisdiction-specific legal requirements, third-party administration of EOR-related obligations, and the pace of transition activities. The Company may also incur additional non-material charges in future periods related to the Plan.

The Company anticipates that the implementation of the Plan will be substantially completed in November 2025. The Company expects the workforce reduction to result in annualized cost savings of approximately $13.6 million, which will begin to be realized in the fourth quarter of 2025.

In addition to the Plan, the Company continues to evaluate further cost optimization other than workforce changes to align its overall cost structure and operational footprint with evolving business needs and market conditions.

Forward-looking statements in this Current Report on Form 8-K, including those regarding the expected timing, costs, and savings related to the Plan, are subject to risks and uncertainties. These risks include, but are not limited to, the Company's ability to complete the workforce reduction as planned and achieve the anticipated benefits related thereto. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time.

**Item 7.01. Regulation FD Disclosure.**

On September 22, 2025, the Company issued a press release announcing the Plan. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits**

---

| | | |
|:---|:---|:---|
| **Exhibit** <br>**Number** |  | **Exhibit Description** |
| 99.1 |  | [Press Release, dated September 22, 2025](mxct-20250922xex99d1.htm) |
| 104 |  | Cover Page Interactive Data (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MaxCyte, Inc.** | **MaxCyte, Inc.** |
| Dated: September 22, 2025 | By: | /s/ Douglas Swirsky |
|  |  | Douglas Swirsky |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability**

**ROCKVILLE, MD, September 22, 2025** — MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a reduction of approximately 34% of the Company's global workforce, inclusive of employees engaged through employer-of-record (EOR) arrangements. Anticipated annualized savings as a result of this action are expected to be approximately $13.6 million.

This workforce reduction is part of MaxCyte's commitment to significantly reduce operating expenses, streamline its organizational structure, and accelerate its path toward profitability. The Company expects this action to yield meaningful cost savings while maintaining focus on its core mission of enabling the next generation of cell therapies.

Consistent with its previously issued outlook, MaxCyte is reiterating that 2025 core revenue is expected to be flat to down approximately 10% compared to 2024. The Company continues to anticipate approximately $5 million in SPL program-related revenue for the full year and expects year-end cash, cash equivalents, and investments to be at least $155 million.

"Today's decision is important to position MaxCyte for long-term success," said Maher Masoud, Chief Executive Officer. "We are grateful to our departing colleagues for their many contributions to MaxCyte's mission and wish them success in future endeavors. This strategic realignment of resources is a significant step forward as part of a broader strategic initiative to drive efficient growth and scale MaxCyte towards profitability. We are developing a culture of continuous improvement throughout the organization and anticipate additional non-employee related opportunities to improve the profitability profile of the company over time. We expect to provide more details on the expected financial impact related to this initiative, as well as the outlook for the remainder of 2025, on our third quarter earnings call in November."

The Company noted that this workforce reduction represents all the anticipated employee-related actions under the restructuring.

**About MaxCyte**

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

------

**MaxCyte Contacts:**

**Investor Relations**

***Gilmartin Group***

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

**Media Contact**

***Oak Street Communications***

Kristen White

kristen@oakstreetcommunications.com

415.608.6060 **Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy, plans and objectives of management for future operations, and anticipated benefits of the announced adjustments to the workforce are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 6, 2025. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

------